Diretriz para uso de agonistas do receptor de GLP-1 e inibidores de SGLT-2 para redução do risco cardiorrenal em adultos.

2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults – Canadian Journal of Cardiology

Ver revisão sistemática relacionada: The Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists on Cardiorenal Outcomes: Systematic Review and Meta-analysis – Canadian Journal of Cardiology

Comentário no Twitter (fio – clique para saber mais)

https://mobile.twitter.com/CJCJournals/status/1557751107006472193